United States

Wisconsin awards grant to Bridge to Cures to commercialize university R&D

Wednesday, April 30, 2014 11:32 AM

In an effort to deliver the benefits of medical discovery to patients seeking relief, the Wisconsin Economic Development Corporation (WEDC) has awarded a $140,000 grant to Bridge to Cures (B2C), a new nonprofit, to establish a new seed fund. The matching grant will enable B2C to provide seed money to entrepreneurs at academic institutions in southeastern Wisconsin seeking to translate their medical research and inventions into products and companies in the healthcare space.

More... »

WIRB Copernicus Group

Rutgers receives $26M antibiotics grant from NIH

Wednesday, April 30, 2014 11:26 AM

The National Institute of Allergy and Infectious Diseases (NIAID) of the NIH has selected infectious disease expert David Perlin, executive director of the Public Health Research Institute at Rutgers New Jersey Medical School, to lead a major research effort aimed at developing new forms of antibiotics to regain the upper hand over deadly bacteria that have become resistant to current treatments.  

More... »

CRF Health eCOA webinar series

Michael S. Gordon named medical director for cancer center trials at Scottsdale Healthcare

Friday, April 25, 2014 11:21 AM

Michael S. Gordon, M.D., has been named the new medical director for the Virginia G. Piper Cancer Center Clinical Trials program at Scottsdale Healthcare. Gordon will oversee the center's phase I clinical trials program. Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with Translational Genomics Research Institute, is a clinical research site for phase I studies of new cancer drugs.

More... »

Report: Inventor incentives could spur medical innovation, cut spending

Wednesday, April 23, 2014 01:55 PM

To help rein in massive healthcare spending, a new RAND study concludes U.S. policymakers should urgently find ways to incentivize pharmaceutical companies and device makers to develop products that produce more value. RAND is a research organization that develops solutions to public policy challenges.

More... »

Scripps Florida Scientists awarded $2M for anti-diabetic drug design

Wednesday, April 23, 2014 01:46 PM

The NIH has awarded scientists from the Florida campus of The Scripps Research Institute (TSRI) $2.1 million to study the therapeutic potential of safer and more effective alternatives to the current crop of anti-diabetic drugs, which have been limited in their use due to side effects including bone loss and congestive heart failure.

More... »

GSK, Genmab receive FDA approval for Arzerra (ofatumumab) for CLL

Monday, April 21, 2014 09:27 AM

GlaxoSmithKline and Genmab have announced that the FDA has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.

More... »

Arsenal Capital acquires Synchrogenix for regulatory writing, submission services, will merge it with Certara

Tuesday, April 15, 2014 01:11 PM

Arsenal Capital Partners, a private equity firm that acquired software and scientific consulting services provider Certara last December, now has purchased Synchrogenix, an independent regulatory-writing CRO, and will merge the two.

More... »

FDA approves expanded indication for certain pacemakers and defibrillators

Friday, April 11, 2014 01:38 PM

The FDA has approved an application from Medtronic for revised labeling for two cardiac resynchronization pacemakers (CRT-P) and eight cardiac resynchronization defibrillators (CRT-D), expanding the indication for use to patients with atrioventricular (AV) block and less severe heart failure.

More... »

CTI Clinical Trial and Consulting Services to open new office

Thursday, April 3, 2014 10:58 AM

CTI Clinical Trial and Consulting Services, a global, privately held, full-service CRO, will relocate the company’s Consulting and Health Economics and Outcomes Research (HECOR) divisions to University Station adjacent to the Xavier University campus in Cincinnati, Ohio.

More... »

FDA grants IND approval for CardioCell’s phase IIa itMSC Therapy trial

Wednesday, April 2, 2014 03:41 PM

CardioCell, a global biotechnology company, has just received the FDA’s Investigational New Drug (IND) approval for a U.S.-based, phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with chronic heart failure (CHF), which generates more than one million hospitalizations annually. Preparation is underway to initiate the study at Emory University, Northwestern University and the University of Pennsylvania in May 2014.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs